Hepatocellular Carcinoma in a 55-Year-Old with Chronic Hepatitis B: A Case Report on Diagnosis and Management
Keywords:
Hepatocellular Carcinoma, Chronic Hepatitis B Virus , Liver CancerAbstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, particularly in regions with a high prevalence of chronic hepatitis B virus (HBV) infection. This case report details the clinical presentation, diagnosis, and management of a 55-year-old male with chronic HBV infection who developed advanced HCC. The patient presented with right upper quadrant pain, weight loss, and jaundice. Diagnostic imaging and biopsy confirmed HCC with portal vein invasion. The patient underwent transarterial chemoembolization (TACE) and was treated with sorafenib. Despite initial response, the disease progressed, and the patient ultimately succumbed to hepatic failure. This case underscores the challenges of managing advanced HCC in patients with cirrhosis and highlights the importance of early detection through regular surveillance in high-risk populations. It also emphasizes the need for a multidisciplinary approach in optimizing outcomes for HCC patients in resource-limited settings like Bangladesh.
References
1. Tufael, Md Mostafizur Rahman et al. (2024). Combined Biomarkers for Early Diagnosis of Hepatocellular Carcinoma, Journal of Angiotherapy, 8(5), 1-12, 9665
2. Llovet, J. M., & Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37(2), 429-442.
3. Tufael, Auditi Kar et al., (2024). Diagnostic Efficacy of Tumor Markers AFP, CA19-9, and CEA in Hepatocellular Carcinoma Patients, Journal of Angiotherapy, 8(4), 1-10, 9513
4. Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., ... & Panel of Experts in HCC-Design Clinical Trials. (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute, 100(10), 698-711.
5. Tufael, Auditi Kar, Vijay Jagdish Upadhye et al., (2024). Serum Biomarkers' Significance and Gender-Specific Hepatocellular Carcinoma Insights of Fishers Patient in Bangladesh, Journal of Angiotherapy, 8(1), 1-9, 9440
6. Sherman, M. (2005, May). Hepatocellular carcinoma: epidemiology, risk factors, and screening. In Seminars in liver disease (Vol. 25, No. 02, pp. 143-154).
7. Khan, A. R., Wei, X., & Xu, X. (2021). Portal vein tumor thrombosis and hepatocellular carcinoma–the changing tides. Journal of Hepatocellular Carcinoma, 1089-1115.
8. Dasse, K. D., Lander, M. J., & Novelli, P. M. (2016). Chemoembolization with drug-eluting beads for the treatment of hepatocellular carcinoma. Journal of the Advanced Practitioner in Oncology, 7(7), 764.
9. Roderburg, C., Tacke, F., & Trautwein, C. (2016). Antiviral therapy in patients with viral hepatitis and hepatocellular carcinoma: indications and prognosis. Visceral medicine, 32(2), 121-126.
10. Bruix, J., & Sherman, M. (2005). Management of hepatocellular carcinoma. Hepatology, 42(5), 1208-123.
